These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24468412)

  • 41. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
    Levine A; Shevah O; Shabat-Sehayek V; Aeed H; Boaz M; Moss SF; Niv Y; Avni Y; Shirin H
    Aliment Pharmacol Ther; 2004 Jul; 20(1):117-22. PubMed ID: 15225178
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification and synthesis of potential impurities of rabeprazole sodium.
    Pingili RR; Jambula MR; Ganta MR; Ghanta MR; Sajja E; Sundaram V; Boluggdu VB
    Pharmazie; 2005 Nov; 60(11):814-8. PubMed ID: 16320941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The proton-pump inhibitors: similarities and differences.
    Horn J
    Clin Ther; 2000 Mar; 22(3):266-80; discussion 265. PubMed ID: 10963283
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-Trichomonas vaginalis activity of synthetic lipophilic diamine and amino alcohol derivatives.
    Giordani RB; De Almeida MV; Fernandes E; França da Costa C; De Carli GA; Tasca T; Zuanazzi JA
    Biomed Pharmacother; 2009 Sep; 63(8):613-7. PubMed ID: 19013752
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study.
    Bharathi DV; Hotha KK; Jagadeesh B; Chatki PK; Thriveni K; Mullangi R; Naidu A
    Biomed Chromatogr; 2009 Jul; 23(7):732-9. PubMed ID: 19360758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proton pump inhibitors: an update.
    Vanderhoff BT; Tahboub RM
    Am Fam Physician; 2002 Jul; 66(2):273-80. PubMed ID: 12152963
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Normal and proton pump inhibitor-mediated gastrin levels in infants 1 to 11 months old.
    Treem W; Hu P; Sloan S
    J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):520-6. PubMed ID: 23689261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.
    McNicholl AG; Linares PM; Nyssen OP; Calvet X; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):414-25. PubMed ID: 22803691
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does rabeprazole enhance distension-induced gastric accommodation?
    Sanaka M; Yamamoto T; Kuyama Y
    Dig Dis Sci; 2009 Feb; 54(2):416-8. PubMed ID: 18594974
    [No Abstract]   [Full Text] [Related]  

  • 50. Stereoselective Pharmacodynamics and Pharmacokinetics of Proton Pump Inhibitors.
    Yang ZC; Yu F; Wang YQ; Wei JF
    Curr Drug Metab; 2016; 17(7):692-702. PubMed ID: 27683046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rabeprazole: A comprehensive profile.
    Bakheit AH; Al-Kahtani HM; Albraiki S
    Profiles Drug Subst Excip Relat Methodol; 2021; 46():137-183. PubMed ID: 33461697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intramolecular nonbonded S...N interaction in rabeprazole.
    Hayashi K; Ogawa S; Sano S; Shiro M; Yamaguchi K; Sei Y; Nagao Y
    Chem Pharm Bull (Tokyo); 2008 Jun; 56(6):802-6. PubMed ID: 18520084
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis of a DOTA (Gd3+)-conjugate of proton-pump inhibitor pantoprazole for gastric wall imaging studies.
    Maharvi GM; Bharucha AE; Fauq AH
    Bioorg Med Chem Lett; 2013 May; 23(9):2808-11. PubMed ID: 23511016
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Site selective syntheses of [(3)H]omeprazole using hydrogen isotope exchange chemistry.
    Pollack SR; Schenk DJ
    J Labelled Comp Radiopharm; 2015; 58(11-12):433-41. PubMed ID: 26380956
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An analysis of the biopharmaceutical behaviour of proton pump inhibitors with different physicochemical properties.
    Jiang X; Shen T; Jin Z; Li C; Li Q; Qiu W; Cui Y; Han Z; Hou X; You J
    Life Sci; 2021 Dec; 286():120042. PubMed ID: 34678262
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proton-Pump Inhibitors Suppress T Cell Response by Shifting Intracellular Zinc Distribution.
    Liu W; Jakobs J; Rink L
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674704
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Omeprazole and talampanel as two examples of retrometabolic drug design.
    Andrási F; Berzsenyi P; Farkas L; Körösi J; Hámori T; Botka P; Ling I; Láng T
    Pharmazie; 2004 May; 59(5):365-6. PubMed ID: 15212302
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases.
    Stockman BJ; Kaur A; Persaud JK; Mahmood M; Thuilot SF; Emilcar MB; Canestrari M; Gonzalez JA; Auletta S; Sapojnikov V; Caravan W; Muellers SN
    J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305530
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spectroscopic study of in situ-formed metallocomplexes of proton pump inhibitors in water.
    Abramenko N; Kejík Z; Kaplánek R; Tatar A; Brogyányi T; Pajková M; Sýkora D; Veselá K; Antonyová V; Dytrych P; Ikeda-Saito M; Martásek P; Jakubek M
    Chem Biol Drug Des; 2021 Feb; 97(2):305-314. PubMed ID: 32854159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective Targeting of Virus Replication by Proton Pump Inhibitors.
    Watanabe SM; Ehrlich LS; Strickland M; Li X; Soloveva V; Goff AJ; Stauft CB; Bhaduri-McIntosh S; Tjandra N; Carter C
    Sci Rep; 2020 Mar; 10(1):4003. PubMed ID: 32132561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.